Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Robert R. Henry(United States Department of Veterans Affairs), Steven C. Griffen(Io Therapeutics (United States)), Steven V. Edelman(University of California San Diego), Sreeneeranj Kasichayanula(Gilead Sciences (United States)), Julio Rosenstock(Velocity Clinical Research (United States)), Alexandros-Georgios Chalamandaris(Bristol-Myers Squibb (Belgium)), Nayyar Iqbal(Chinese University of Hong Kong), Sunder Mudaliar(University of California San Diego), James F. List(Bristol-Myers Squibb (United States)), Allyson Bogle(Bristol-Myers Squibb (United States))
Cited by 238
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
|New England Journal of Medicine|2006|1.3k
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
|Endocrine Practice|2016|875
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
|Patient Preference and Adherence|2016|758